These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 2529825)
21. Prolonged suppression of rat testis function by a depot formulation of Zoladex, a GnRH agonist. Ward JA; Furr BJ; Valcaccia B; Curry B; Bardin CW; Gunsalus GL; Morris ID J Androl; 1989; 10(6):478-86. PubMed ID: 2533593 [TBL] [Abstract][Full Text] [Related]
22. Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial. Metz R; Namer M; Adenis L; Audhuy B; Bugat R; Colombel P; Couette JE; Grise P; Khater R; LePorz B Am J Clin Oncol; 1988; 11 Suppl 2():S112-4. PubMed ID: 2977263 [TBL] [Abstract][Full Text] [Related]
23. Treatment of breast cancer with gonadotropin-releasing hormone. Manni A; Santen R; Harvey H; Lipton A; Max D Endocr Rev; 1986 Feb; 7(1):89-94. PubMed ID: 3082618 [TBL] [Abstract][Full Text] [Related]
24. Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot. Costantini S; Anserini P; Valenzano M; Remorgida V; Venturini PL; De Cecco L Eur J Obstet Gynecol Reprod Biol; 1990 Oct; 37(1):63-9. PubMed ID: 2142921 [TBL] [Abstract][Full Text] [Related]
25. [Therapy with gonadotropin releasing hormone agonists (zoladex) in premenopausal females with metastastic breast cancer]. Kaufmann M; Schmid H; Kiesel L; Klinga K Geburtshilfe Frauenheilkd; 1988 Jul; 48(7):528-32. PubMed ID: 2975241 [TBL] [Abstract][Full Text] [Related]
26. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections. Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598 [TBL] [Abstract][Full Text] [Related]
27. Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer. Denis L; Keuppens F; Mahler C; Debruyne FM; Weil EH; Lunglmayr G; Newling D; Robinson MR; Richards B; Smith PH Prog Clin Biol Res; 1987; 243A():221-7. PubMed ID: 2958852 [No Abstract] [Full Text] [Related]
28. Effective long-term suppression of pituitary-gonadal axis in prostatic cancer by Zoladex (ICI 118,630). Murphy GP; Greco J; Huben R Urology; 1987 Nov; 30(5):482-3. PubMed ID: 2960064 [TBL] [Abstract][Full Text] [Related]
29. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630. Plowman PN; Nicholson RI; Walker KJ Br J Cancer; 1986 Dec; 54(6):903-9. PubMed ID: 2948537 [TBL] [Abstract][Full Text] [Related]
30. Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancer. Falkson CI; Falkson HC; Falkson G Eur J Cancer; 1991; 27(10):1208-11. PubMed ID: 1835587 [TBL] [Abstract][Full Text] [Related]
31. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot. Hjertberg H; Varenhorst E; Svensson M; Kågedal B; Nordenskjöld B Acta Oncol; 1988; 27(4):361-4. PubMed ID: 2974290 [TBL] [Abstract][Full Text] [Related]
32. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. West CP; Lumsden MA; Lawson S; Williamson J; Baird DT Fertil Steril; 1987 Jul; 48(1):45-51. PubMed ID: 2954863 [TBL] [Abstract][Full Text] [Related]
35. Endocrinology of Zoladex in postmenopausal women. Dowsett M; Cantwell BM; Harris AL Horm Res; 1989; 32 Suppl 1():209-12. PubMed ID: 2533152 [TBL] [Abstract][Full Text] [Related]
36. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma]. Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer. Perren TJ; Clayton RN; Blackledge G; Bailey LC; Holder G; Lynch SS; Arkell DG; Cottam J; Farrar D; Young CH Cancer Chemother Pharmacol; 1986; 18(1):39-43. PubMed ID: 2944668 [TBL] [Abstract][Full Text] [Related]
38. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy. Grant JB; Ahmed SR; Shalet SM; Costello CB; Howell A; Blacklock NJ Br J Urol; 1986 Oct; 58(5):539-44. PubMed ID: 2946356 [TBL] [Abstract][Full Text] [Related]
39. [Buserelin therapy in postmenopausal patients with advanced breast carcinoma]. Vici P; Veltri E; Carpano S; Di Lauro L; Lopez M Clin Ter; 1991 Feb; 136(3):195-9. PubMed ID: 1827382 [TBL] [Abstract][Full Text] [Related]
40. Experience with a depot GnRH-agonist (Zoladex) in the treatment of genital endometriosis. Mettler L; Steinmüller H; Schachner-Wünschmann E Hum Reprod; 1991 May; 6(5):694-8. PubMed ID: 1834693 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]